Odonate Therapeutics, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Odonate Therapeutics, Inc. reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$30.16 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-04-28.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2020-04-28
- Odonate Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-03-31 was -$30.16M.
- Odonate Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2019-12-31 was -$27.85M.
- Odonate Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2019-09-30 was -$26.63M.
- Odonate Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2019-06-30 was -$28.70M.
- Odonate Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was -$111.83M.
- Odonate Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2018 was -$88.96M.
- Odonate Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2017 was -$32.74M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2020-03-31 | -$30.16M 10-Q · filed 2020-04-28 | -$58.01M derived: sum of 2 quarters · filed 2020-04-28 | -$84.64M derived: sum of 3 quarters · filed 2020-04-28 | -$113.34M derived: sum of 4 quarters · filed 2020-04-28 |
| 2019-12-31 | -$27.85M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | -$54.48M derived: sum of 2 quarters · filed 2020-02-20 | -$83.18M derived: sum of 3 quarters · filed 2020-02-20 | -$111.83M 10-K · filed 2020-02-20 |
| 2019-09-30 | -$26.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$55.33M derived: sum of 2 quarters · filed 2019-11-06 | -$83.97M 10-Q · filed 2019-11-06 | -$112.74M derived: sum of 4 quarters · filed 2020-04-28 |
| 2019-06-30 | -$28.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | -$57.35M 10-Q · filed 2019-07-24 | -$86.11M derived: sum of 3 quarters · filed 2020-04-28 | -$110.04M derived: sum of 4 quarters · filed 2020-04-28 |
| 2019-03-31 | -$28.64M 10-Q · filed 2020-04-28 | -$57.41M derived: sum of 2 quarters · filed 2020-04-28 | -$81.33M derived: sum of 3 quarters · filed 2020-04-28 | -$100.72M derived: sum of 4 quarters · filed 2020-04-28 |
| 2018-12-31 | -$28.76M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | -$52.69M derived: sum of 2 quarters · filed 2020-02-20 | -$72.08M derived: sum of 3 quarters · filed 2020-02-20 | -$88.96M 10-K · filed 2020-02-20 |
| 2018-09-30 | -$23.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$43.32M derived: sum of 2 quarters · filed 2019-11-06 | -$60.20M 10-Q · filed 2019-11-06 | -$75.94M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | -$19.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | -$36.27M 10-Q · filed 2019-07-24 | -$52.02M derived: sum of 3 quarters · filed 2019-07-24 | |
| 2018-03-31 | -$16.88M 10-Q · filed 2019-04-25 | -$32.63M derived: sum of 2 quarters · filed 2019-04-25 | ||
| 2017-12-31 | -$15.75M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | -$32.74M 10-K · filed 2019-02-22 | ||
| 2017-09-30 | -$17.00M 10-Q · filed 2018-10-23 |